Janssen Reports Positive Phase III Data for Chronic Diabetic Peripheral …Genetic Engineering NewsJanssen Pharmaceuticals reported Phase III results demonstrating the efficacy of Nucynta® ER (extended release tapentadol) in managing pain associated with chronic diabetic peripheral neuropathy (DPN). Janssen says the data is consistent with that of a …Janssen tapentadol drug found to reduce pain in [...]
